SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months

Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency

First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices

Briefs: Neuland Laboratories, Cipla and Zydus

Cipla has received 8 inspectional observations in Form 483

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year

Briefs: Piramal Pharma, Alembic Pharmaceuticals

USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA

Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

IOL Chemicals and Pharmaceuticals Q3 FY23 income down 6%

The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins